Abstract:The transcription factor CCAAT/enhancer‐binding protein β (C/EBPβ) is highly expressed in various tissues during development, including liver, adipose tissue, blood cells, lung and the endocrine pancreas. Two isoforms of C/EBPβ namely liver‐enriched activator protein (LAP) and liver‐enriched inhibitor protein (LIP) translated from the same mRNA have been described. The LAP and LIP isoforms share the same C‐terminal DNA binding domain except LAP has an extra N‐terminal activation domain. Probably due to its higher affinity for its DNA cognate sequences, the LIP can counteract the effects of LAP isoforms even at substoichiometric levels. In vitro and in vivo experiments with cultured cells and knockout mice demonstrated that C/EBPβ play a critical role in the regulation of myofibroblast differentiation and bleomycin induced pulmonary fibrosis. However, the regulatory mechanism of C/EBPβ gene expression is unclear. Analysis of the C/EBPβ promoter sequence identified a conserved P53 response element (P53RE) in the C/EBPβ gene promoter. Gel shift mobility and chromatin immunoprecipitation assays confirmed that P53 binds to the P53RE. Promoter reporter assays and real time PCR analysis of samples from fibroblasts transiently transfected with P53 or dominant negative P53 expression plasmids indicated that P53 was a repressor of C/EBPβ gene transcription. Western blot analysis with protein extracts from similarly transfected fibroblasts or P53 deficient fibroblasts showed that P53 differentially regulated translation of the C/EBPβ LAP and LIP isoforms through the regulation of eIF4E and eIF4E‐BP1. Further studies with constructs containing the LAP 5′ untranslated region or the LIP 5′ untranslated region showed that the 5′ untranslated region is important in differential control of C/EBPβ LAP and LIP translation. Thus P53 could regulate C/EBPβ gene expression at both transcriptional and translational levels. Support or Funding Information This work was supported by grants HL052285 and HL112880 from the National Institute of Health.

P53-Dependent Suppression Of Uridine Phosphorylase Gene Expression Through Direct Promoter Interaction

DEPTOR is a Direct P53 Target That Suppresses Cell Growth and Chemosensitivity

P53 represses pyrimidine catabolic gene dihydropyrimidine dehydrogenase (DPYD) expression in response to thymidylate synthase (TS) targeting

The P53-Induced Oncogenic Phosphatase PPM1D Interacts with Uracil DNA Glycosylase and Suppresses Base Excision Repair.

P53 Inactivation Upregulates P73 Expression Through E2F-1 Mediated Transcription.

Evaluating the Influence of a G-Quadruplex Prone Sequence on the Transactivation Potential by Wild-Type and/or Mutant P53 Family Proteins through a Yeast-Based Functional Assay

p53 Deficiency leads to compensatory up-regulation of p16INK4a.

P53 and Its Downstream Proteins As Molecular Targets of Cancer

A Newly Identified Dependence Receptor UNC5H4 is Induced During DNA Damage-Mediated Apoptosis and Transcriptional Target of Tumor Suppressor P53.

P53 Suppresses E2f1-Dependent Plk1 Expression Upon Dna Damage by Forming P53-E2f1-Dna Complex

Tumor Suppressor P53 Can Participate in Transcriptional Induction of the GADD45 Promoter in the Absence of Direct DNA Binding

p53 exerts anticancer effects by regulating enhancer formation and activity

Transcriptional Regulation of Estrogen Receptor-Alpha by P53 in Human Breast Cancer Cells

Inhibition of USP14 Deubiquitinating Activity As a Potential Therapy for Tumors with P53 Deficiency

UPP1 Promotes Lung Adenocarcinoma Progression through Epigenetic Regulation of Glycolysis

Elucidating the chain of command: our current understanding of critical target genes for p53-mediated tumor suppression

Single-cell Transcriptomic Profiling of Non-Hematopoietic Circulating Cells in Mid-Gestational Mouse Embryos.

Mutant p53 drives cancer chemotherapy resistance due to loss of function on activating transcription of PUMA

Transcriptional and translational regulation of CCAAT/Enhancer Binding Protein β expression by P53

Ubiquitin-specific protease 54 regulates GLUT1-mediated aerobic glycolysis to inhibit lung adenocarcinoma progression by modifying p53 degradation

Transcription activity is required for p53-dependent tumor suppression